Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Finished Goods (2020 - 2025)

Cytek Biosciences' Finished Goods history spans 6 years, with the latest figure at $11.5 million for Q4 2025.

  • For Q4 2025, Finished Goods fell 22.78% year-over-year to $11.5 million; the TTM value through Dec 2025 reached $11.5 million, down 22.78%, while the annual FY2025 figure was $11.5 million, 22.78% down from the prior year.
  • Finished Goods reached $11.5 million in Q4 2025 per CTKB's latest filing, down from $20.3 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $22.8 million in Q1 2023 to a low of $9.1 million in Q2 2021.
  • Average Finished Goods over 5 years is $15.4 million, with a median of $15.2 million recorded in 2025.
  • Peak YoY movement for Finished Goods: surged 86.31% in 2022, then crashed 34.36% in 2024.
  • A 5-year view of Finished Goods shows it stood at $12.6 million in 2021, then increased by 29.48% to $16.3 million in 2022, then dropped by 9.96% to $14.7 million in 2023, then increased by 0.88% to $14.8 million in 2024, then decreased by 22.78% to $11.5 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Finished Goods are $11.5 million (Q4 2025), $20.3 million (Q3 2025), and $16.9 million (Q2 2025).